A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

Childhood-Onset Fluency Disorder Clinical Trial

Official title:

A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Ten-week Prospective Study to Evaluate the Efficacy and Safety of NOE-105 in Adult Male Patients With Childhood Onset Fluency Disorder (Orpheus)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05583955
• Other study ID #: NOE-CFD-201
• Status: Completed
• Phase: Phase 2
• Start date: July 25, 2022
• Est. completion date: November 24, 2023

Study information

• Verified date: March 2024
• Source: Noema Pharma AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to evaluate the effectiveness of NOE-105 on speech fluency without the known antipsychotic-induced side effects of commonly used treatments for childhood onset fluency disorder (COFD).

Description:

NOE-105 is an investigational selective PDE10A inhibitor with a potential therapeutic effect for the treatment of COFD. In this study adult male patients may be randomized to a double-blind, placebo-controlled, parallel group treatment with NOE-105 or placebo once daily. The study is designed to find the maximum tolerated dose of NOE-105 and thereafter, to maintain the participants at this dose until they have completed a total of 10 weeks treatment period. Following up to 10 weeks of treatment, participants will visit the study site for a follow-up visit within 28 (± 7) days of the date of the last dose of study treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: November 24, 2023
• Est. primary completion date: October 20, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Patients must be 18 to 55 years of age inclusive, at the time of signing the informed consent.

2. Patients who satisfy DSM-5 criteria for childhood onset fluency disorder and are suitable for pharmacotherapy.

3. Have a history of stuttering for more than or equal to = 2 years with onset consistent to developmental in nature before age 8 years.

4. Patient reported global stuttering experience as "moderate" at screening and baseline.

5. Patients must discontinue all medications used to treat stuttering for at least 14 days prior to receiving study treatment. With the exception of antipsychotic therapies (see exclusion criterion #11), other psychotropic drugs will be allowed provided they have been stable for at least 14 days prior to receiving study treatment and are expected to remain stable for the duration of the study.

6. BMI within the range 19 to 35 kg/m2 (inclusive).

7. Male Contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Male patients must use a condom during the treatment period and until the end of relevant systemic exposure in the male participant, plus a further 90-day period. In addition, for a non-pregnant WOCBP partner.

8. Capable of giving signed informed consent

9. Able to read and write in English

Exclusion Criteria:

1. Stuttering is related to a known neurological cause eg, stroke, etc.

2. Low IQ in the opinion of the investigator.

3. Patients with uncontrolled seizure disorders.

4. A history of severe traumatic brain injury or stroke.

5. Patients who are, in the investigator's opinion, at imminent risk of suicide.

6. Known to have tested positive for human immunodeficiency virus.

7. Known DSM-5 diagnosis of substance abuse or dependence.

8. Unstable medical illness or clinically significant abnormalities on screening tests/exams.

9. Any unstable medical conditions or are currently ill (eg, congenital heart disease, arrhythmia or cancer), which, in the investigator's judgment, will put them at a risk of major adverse event during this trial, are expected to progress during the study, or will interfere with safety and efficacy assessments.

10. Initiation of new behavioral therapies for stuttering within 10 weeks prior to baseline.

11. Use of antipsychotic drug therapy within 14 days prior to receiving treatment until the EoT visit.

12. Participation in another clinical study with an IP administered in the last 30 days.

13. Participants with a known hypersensitivity to NOE-105 or any of the excipients of the product.

14. Patient must not intend to use cannabinoids, cocaine, or nonprescribed opiates.

15. Involvement in the planning and/or conduct of the study (applies to both Noema staff and/or staff at the study site).

16. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.

17. Previous randomization in the present study.

Related Conditions & MeSH terms

• Childhood-Onset Fluency Disorder

Intervention

Drug:
• NOE-105
Escalating dose levels of NOE-105 will be given and maximum tolerated dose will be maintained
• Placebo
Escalating dose levels of matching Placebo will be given

Locations

Country	Name	City	State
Australia	Noema Investigator site	Brookvale	New South Wales
Australia	Noema Investigator site	Miranda	New South Wales
Australia	Noema Investigator site	Sydney	New South Wales
United States	Noema Investigator site	Bellflower	California
United States	Noema Investigator site	Berlin	New Jersey
United States	Noema Investigator site	Jacksonville	Florida
United States	Noema Investigator site	Memphis	Tennessee
United States	Noema Investigator site	Orlando	Florida
United States	Noema Investigator site	Overland Park	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
Noema Pharma AG

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline to end point in severity subset of the MLGSSS	MLGSSS refers to Maguire-Leal-Garibaldi Self-rated Stuttering Scale	Up to 71 days
Primary	Number of participants with adverse events	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment	Up to 71 days
Primary	Severity of the adverse events	Adverse events will be categorized as mild, moderate or severe by the investigator	Up to 71 days
Primary	Change in the hematological parameters	Platelet count, RBC count, Hemoglobin, hematocrit and differential WBC count will be assessed	Up to 71 days
Primary	Change in clinical chemistry	Urea, creatinine, potassium, SGOT, SGPT, glucose, sodium chloride, magnesium, phosphates, calcium, total and conjugated bilirubin, GGT, total protein albumin, phosphokinase, and plasma prolactin will be assessed	Up to 71 days
Primary	Change in the vital signs	Temperature, weight, height, pulse rate and blood pressure will be assessed.	Up to 71 days
Secondary	Change from baseline to end point in SDS	SDS refers to Sheehan disability scale	Up to 71 days
Secondary	PGI-S rating at end point	PGI-S refers to patient global impression of severity	Up to 71 days
Secondary	CGI-C rating at end point	Clinician global impression of change	Up to 71 days
Secondary	Rating of the medication satisfaction questionnaire at end point	To evaluate the patient's satisfaction in treatment with NOE-105	Up to 71 days
Secondary	Change from baseline to end point in clinician-rated stuttering severity instrument-4	To evaluate the effect of NOE-105 on the change in stuttering severity	Up to 71 days
Secondary	PGI-C rating at end point	PGI-C refers to patient global impression of change	Up to 71 days
Secondary	Change in mood as rated by the patient through change from baseline to end point in Quick inventory of depressive symptomology (QIDS-16)		Up to 71 days